Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II randomized double-blind placebo-controlled study of HS-10519 in adults with depression and acute suicidal ideation or behavior
CTR20250883Phase 2Active
- Sponsor
- Hengrui Therapeutics
- Start
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of arketamine hydrochloride in major depressive disorder (MDD), sponsored by Hengrui Therapeutics. Started Mar 2025; status: active.
02
Drugs
arketamine hydrochloride
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on CTR20250883.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20250883.